Alexion Pharma (ALXN) Tops Q4 EPS by 20c, FY Guidnace Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Pharmaceuticals (ALXN) PT Lowered to $161 at Deutsche Bank Following 4Q Report
February 9, 2018 7:22 AM ESTDeutsche Bank lowered its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $161.00 (from $163.00) while maintaining a Buy rating following the company's 4Q earnings report. Alexion reported total sales that topped consensus expectations (+3.4% vs Street) with the beat largely driven primarily by volume growth across all... More
